title: Combined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized Rats.
abstract: The purpose of this study was to investigate the effects of three weeks of rosuvastatin (Ros) treatment alone and in combination with voluntary training (Tr) on expression of genes involved in cholesterol metabolism (LDLR, PCSK9, LRP-1, SREBP-2, IDOL, ACAT-2 and HMGCR) in the liver of eight week-old ovariectomized (Ovx) rats. Sprague Dawley rats were Ovx or sham-operated (Sham) and kept sedentary for 8 weeks under a standard diet. Thereafter, rats were transferred for three weeks in running wheel cages for Tr or kept sedentary (Sed) with or without Ros treatment (5mg/kg/day). Six groups were formed: Sham-Sed treated with saline (Sal) or Ros (Sham-Sed-Sal; Sham-Sed-Ros), Ovx-Sed treated with Sal or Ros (Ovx-Sed-Sal; Ovx-Sed-Ros), Ovx trained treated with Sal or Ros (Ovx-Tr-Sal; Ovx-Tr-Ros). Ovx-Sed-Sal rats depicted higher (P < 0.05) body weight, plasma total cholesterol (TC) and LDL-C, and liver TC content compared to Sham-Sed-Sal rats. In contrast, mRNA levels of liver PCSK9, LDLR, LRP-1 as well as plasma PCSK9 concentrations and protein levels of LRP-1 were reduced (P < 0.01) in Ovx-Sed-Sal compared to Sham-Sed-Sal rats. However, protein levels of LDLR increased (P < 0.05) in Ovx-Sed-Sal compared to Sham-Sed-Sal rats. Treatment of Ovx rats with Ros increased (P < 0.05) mRNA and protein levels of LRP-1 and PCSK9 but not mRNA levels of LDLR, while its protein abundance was reduced at the level of Sham rats. As a result, plasma LDL-C was not reduced. Exercise alone did not affect the expression of any of these markers in Ovx rats. Overall, Ros treatment corrected Ovx-induced decrease in gene expression of markers of cholesterol metabolism in liver of Ovx rats, but without reducing plasma LDL-C concentrations. Increased plasma PCSK9 levels could be responsible for the reduction of liver LDLR protein abundance and the absence of reduction of plasma LDL-C after Ros treatment.
authors.affiliation: Laboratory of molecular cell biology, Montreal heart institute, Montréal (QC) Canada.|Department of medicine, Faculté de médecine, Université de Montréal, Montréal (QC) Canada.
authors.forename: Emilienne Tudor
authors.initials: ET
authors.lastname: Ngo Sock
authors.affiliation: Laboratory of molecular cell biology, Montreal heart institute, Montréal (QC) Canada.|Department of pharmacology, Faculté de médecine, Université de Montreal, Montréal (QC) Canada.|Faculté de pharmacie, Université de Montréal, Montréal (QC) Canada.
authors.forename: Gaétan
authors.initials: G
authors.lastname: Mayer
authors.affiliation: Department of kinesiology, Université de Montréal, Montréal (QC) Canada.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Lavoie
mesh_terms: D000818:Animals; D001835:Body Weight; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D008099:Liver / Q000378:metabolism; D010052:Ovariectomy; D010805:Physical Conditioning, Animal; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D000068718:Rosuvastatin Calcium / Q000494:pharmacology*
chemical_list: D012333:RNA, Messenger; D000068718:Rosuvastatin Calcium; D002784:Cholesterol